Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery.
Publication
, Journal Article
Borys, N; Dewhirst, MW
Published in: Adv Drug Deliv Rev
November 2021
We review the drug development of lyso-thermosensitive liposomal doxorubicin (LTLD) which is the first heat-activated formulation of a liposomal drug carrier to be utilized in human clinical trials. This class of compounds is designed to carry a payload of a cytotoxic agent and adequately circulate in order to accumulate at a tumor that is being heated. At the target the carrier is activated by heat and releases its contents at high concentrations. We summarize the preclinical and clinical experience of LTLD including its successes and challenges in the development process.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Adv Drug Deliv Rev
DOI
EISSN
1872-8294
Publication Date
November 2021
Volume
178
Start / End Page
113985
Location
Netherlands
Related Subject Headings
- Polyethylene Glycols
- Pharmacology & Pharmacy
- Hyperthermia, Induced
- Hyperthermia
- Humans
- Drug Liberation
- Drug Development
- Drug Delivery Systems
- Doxorubicin
- Antibiotics, Antineoplastic
Citation
APA
Chicago
ICMJE
MLA
NLM
Borys, N., & Dewhirst, M. W. (2021). Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery. Adv Drug Deliv Rev, 178, 113985. https://doi.org/10.1016/j.addr.2021.113985
Borys, Nicholas, and Mark W. Dewhirst. “Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery.” Adv Drug Deliv Rev 178 (November 2021): 113985. https://doi.org/10.1016/j.addr.2021.113985.
Borys N, Dewhirst MW. Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery. Adv Drug Deliv Rev. 2021 Nov;178:113985.
Borys, Nicholas, and Mark W. Dewhirst. “Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery.” Adv Drug Deliv Rev, vol. 178, Nov. 2021, p. 113985. Pubmed, doi:10.1016/j.addr.2021.113985.
Borys N, Dewhirst MW. Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery. Adv Drug Deliv Rev. 2021 Nov;178:113985.
Published In
Adv Drug Deliv Rev
DOI
EISSN
1872-8294
Publication Date
November 2021
Volume
178
Start / End Page
113985
Location
Netherlands
Related Subject Headings
- Polyethylene Glycols
- Pharmacology & Pharmacy
- Hyperthermia, Induced
- Hyperthermia
- Humans
- Drug Liberation
- Drug Development
- Drug Delivery Systems
- Doxorubicin
- Antibiotics, Antineoplastic